Buy Cyproterone acetate and ethinylestradiol

Cyproterone acetate and ethinylestradiol

What Is Cyproterone Acetate and Ethinylestradiol?

Cyproterone acetate and ethinylestradiol is a combination oral medication that contains two active ingredients: cyproterone acetate (a synthetic progestogen with anti-androgen properties) and ethinylestradiol (a synthetic estrogen). It is formulated as a pill delivering a fixed dose of 2 mg cyproterone acetate and 0.035 mg ethinylestradiol per tablet. In Hong Kong, the product is regulated by the Department of Health and is prescribed for women’s health conditions such as moderate to severe acne, hirsutism, and for contraceptive purposes.

How Cyproterone Acetate and Ethinylestradiol Works in the Body

• Cyproterone acetate blocks androgen receptors and reduces the production of testosterone, limiting the effects of male hormones that can cause excess hair growth and acne.
• Ethinylestradiol provides estrogenic activity that stabilises the endometrial lining and suppresses ovulation when taken daily, contributing to the contraceptive effect.
• The combination creates a hormonal environment that reduces sebum production, diminishes hair follicle sensitivity to androgens, and prevents the release of an egg each month.
• Onset of anti-androgen effects typically begins within a few days, while full contraceptive protection is achieved after 7 days of uninterrupted daily dosing.
• Both components are absorbed orally, undergo hepatic metabolism (primarily via CYP3A4), and are eliminated in the urine and bile.

Conditions Treated with Cyproterone Acetate and Ethinylestradiol

• Acne vulgaris (moderate to severe) in women - the anti-androgen action helps clear persistent lesions that have not responded to topical therapy.
• Hirsutism - reduction of unwanted hair growth on the face, chest, and abdomen.
• Contraception - when taken as directed, the formulation prevents ovulation and provides reliable birth control.

These indications are approved by Hong Kong health authorities and are supported by clinical guidelines for hormonal therapy in women.

Evidence-Based Off-Label Uses

Off-Label Use in Gender-Affirming Hormone Therapy

Cyproterone acetate and ethinylestradiol has been studied as part of feminising hormone regimens for transgender women. Randomised trials and cohort studies have demonstrated reductions in testosterone levels and improvements in secondary female sexual characteristics. This use is not approved by regulatory agencies in Hong Kong and requires careful supervision by an endocrinologist or specialist in transgender health.

Disclaimer: Off-label use requires medical supervision and an individualized risk assessment.

Who Should Use Cyproterone Acetate and Ethinylestradiol?

Ideal Patient Profile

• Adult women requiring hormonal control of acne or excess hair growth.
• Women seeking an oral contraceptive who have no contraindications to estrogen-containing products.

Absolute Contraindications

• Known hypersensitivity to cyproterone acetate, ethinylestradiol, or any excipient.
• Current pregnancy or breastfeeding.
• History of or active thromboembolic disease (e.g., deep-vein thrombosis, pulmonary embolism).
• Established estrogen-dependent malignancy (e.g., breast cancer).
• Severe hepatic impairment.

Relative Contraindications

• Controlled hypertension.
• Migraine with aura.
• Smoking in women over 35 years of age.
• Diabetes with vascular complications.

Special Populations

• Pregnancy/Lactation: Use is prohibited; an effective alternative contraceptive method should be employed.
• Elderly Women: Caution is advised; dose adjustments are generally not required but monitoring for cardiovascular risk is prudent.
• Renal or Hepatic Dysfunction: Dose may need modification; refer to a specialist for individualized guidance.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Nausea or mild gastrointestinal upset
• Breast tenderness or enlargement
• Headache
• Weight gain or fluid retention
• Mood changes (e.g., mild depression)

These events are usually transient and improve with continued therapy.

Serious Adverse Events

• Venous thromboembolism (VTE): Sudden leg swelling, pain, or shortness of breath require emergency evaluation.
• Hepatic dysfunction: Jaundice, dark urine, or elevated liver enzymes.
• Severe allergic reaction: Rash, itching, swelling of the face or throat.

If any serious symptoms appear, seek immediate medical attention.

Drug Interactions

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) may increase plasma levels of cyproterone acetate, enhancing anti-androgenic effects and side-effect risk.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine) can reduce efficacy, potentially compromising contraceptive protection.
• Anticoagulants (warfarin) may have altered activity; regular INR monitoring is recommended.
• Other hormonal contraceptives should not be combined, as this may increase thrombotic risk.

Food and Lifestyle Interactions

• The tablet can be taken with or without food; a consistent routine improves adherence.
• Moderate alcohol consumption does not generally interfere, but excessive intake can increase liver strain and VTE risk.
• Driving and operating machinery are not impaired by the medication.

Note: Patients should disclose all current medications, supplements, and herbal products to their healthcare provider before initiating therapy.

How to Take Cyproterone Acetate and Ethinylestradiol

• Standard dosing: One tablet (2 mg/0.035 mg) is taken orally once daily, preferably at the same time each day.
• Missed dose: If a dose is missed and it is less than 24 hours late, take it as soon as remembered. Do not double-dose. If more than 24 hours have passed, start a new pack the next day and use a backup contraceptive method for the subsequent 7 days.
• Renal or hepatic adjustment: Dose reductions may be considered for severe impairment; a prescriber will decide based on laboratory results.
• Storage: Keep the pills at room temperature, away from moisture and direct sunlight. Keep out of reach of children.
• Overdose: Symptoms may include nausea, vomiting, dizziness, or severe headache. Seek emergency medical care; supportive care is the mainstay of treatment.
• Discontinuation: Stopping abruptly may lead to a rapid return of acne or hirsutism. A tapering schedule is rarely needed, but a clinician may recommend an alternative hormonal regimen.

Monitoring and Follow-Up

• Baseline assessment: Blood pressure, liver function tests, and a review of personal or family history of thromboembolic disease before starting therapy.
• Periodic review: Blood pressure and liver enzymes should be rechecked after 3 months and then annually, or sooner if symptoms develop.
• Contraceptive efficacy: Use a backup method (e.g., barrier protection) for the first 7 days of a new pack or after any missed dose.
• Skin evaluation: Monitor acne and hair growth progress; adjustments may be necessary after 2-3 months.

Storage and Handling

• Store at 20-25 °C (68-77 °F), protected from excess humidity and light.
• Do not refrigerate unless instructed by a pharmacist.
• Keep the original container tightly closed; discard any tablets that are discoloured, broken, or past their expiration date.
• For safe disposal, return unused medication to a pharmacy-based take-back program or follow local hazardous waste guidelines.

Medication-Specific Glossary

Anti-androgen

A substance that blocks the effects of male hormones (androgens) on target tissues.

Progestogenic

Referring to a compound that mimics the action of natural progesterone, influencing the menstrual cycle and pregnancy.

Venous Thromboembolism (VTE)

Formation of a blood clot in a vein, which can travel to the lungs (pulmonary embolism) and become life-threatening.

CYP3A4

An enzyme in the liver that metabolises many drugs; its activity can be increased or decreased by other substances, affecting drug levels.

Medical Disclaimer

This article provides educational information about cyproterone acetate and ethinylestradiol and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.